166 related articles for article (PubMed ID: 20384566)
21. Reducing costs and improving hypertension management.
Stankus V; Hemmelgarn B; Campbell NR; Chen G; McAlister FA; Tsuyuki RT
Can J Clin Pharmacol; 2009; 16(1):e151-5. PubMed ID: 19193969
[TBL] [Abstract][Full Text] [Related]
22. Changes in the utilization of venlafaxine after the introduction of generics in Sweden.
Godman B; Persson M; Miranda J; Skiöld P; Wettermark B; Barbui C; Gustafsson LL
Appl Health Econ Health Policy; 2013 Aug; 11(4):383-93. PubMed ID: 23754677
[TBL] [Abstract][Full Text] [Related]
23. Angiotensin-converting enzyme inhibitors (ACEIs), not angiotensin receptor blockers (ARBs), are preferred and effective mode of therapy in high cardiovascular risk patients.
Vijan SG
J Indian Med Assoc; 2009 Mar; 107(3):178-82. PubMed ID: 19810392
[TBL] [Abstract][Full Text] [Related]
24. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
25. Uptake of angiotensin II receptor blockers in the treatment of hypertension.
Greving JP; Denig P; van der Veen WJ; Beltman FW; Sturkenboom MC; de Zeeuw D; Haaijer-Ruskamp FM
Eur J Clin Pharmacol; 2005 Jul; 61(5-6):461-6. PubMed ID: 15912393
[TBL] [Abstract][Full Text] [Related]
26. The impact of ageing and changing utilization patterns on future cardiovascular drug expenditure: a pharmacoepidemiological projection approach.
Kildemoes HW; Andersen M; Støvring H
Pharmacoepidemiol Drug Saf; 2010 Dec; 19(12):1276-86. PubMed ID: 20954165
[TBL] [Abstract][Full Text] [Related]
27. Are specific initiatives required to enhance prescribing of generic atypical antipsychotics in Scotland?: International implications.
Bennie M; Bishop I; Godman B; Barbui C; Raschi E; Campbell S; Miranda J; Gustafsson LL
Int J Clin Pract; 2013 Feb; 67(2):170-80. PubMed ID: 23305478
[TBL] [Abstract][Full Text] [Related]
28. Initiatives to improve prescribing efficiency for drugs to treat Parkinson's disease in Croatia: influence and future directions.
Brkicic LS; Godman B; Voncina L; Sovic S; Relja M
Expert Rev Pharmacoecon Outcomes Res; 2012 Jun; 12(3):373-84. PubMed ID: 22812560
[TBL] [Abstract][Full Text] [Related]
29. Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global relevance.
Godman B; Wettermark B; Hoffmann M; Andersson K; Haycox A; Gustafsson LL
Expert Rev Pharmacoecon Outcomes Res; 2009 Feb; 9(1):65-83. PubMed ID: 19371180
[TBL] [Abstract][Full Text] [Related]
30. Impact of drug price adjustments on utilization of and expenditures on angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in Taiwan.
Huang SH; Hsu CN; Yu SH; Cham TM
BMC Public Health; 2012 May; 12():288. PubMed ID: 22521158
[TBL] [Abstract][Full Text] [Related]
31. Use and cost of branded and generic drugs in patients with coronary heart disease--results from a prospective survey of 1008 patients in two London hospitals.
Corp EV; Antoniou S; Wright PG; Khachi H; Vercaeren S; Wald DS
QJM; 2009 Dec; 102(12):843-9. PubMed ID: 19828644
[TBL] [Abstract][Full Text] [Related]
32. Measures to improve angiotensin receptor blocker prescribing efficiency in the UK: findings and implications.
Martin A; Godman B; Miranda J; Tilstone J; Saleem N; Olsson E; Acosta A; Restrepo L; Bennie M
J Comp Eff Res; 2014 Jan; 3(1):41-51. PubMed ID: 24345256
[TBL] [Abstract][Full Text] [Related]
33. Effects of renin-angiotensin system blockers on renal outcomes and all-cause mortality in patients with diabetic nephropathy: an updated meta-analysis.
Sarafidis PA; Stafylas PC; Kanaki AI; Lasaridis AN
Am J Hypertens; 2008 Aug; 21(8):922-9. PubMed ID: 18535536
[TBL] [Abstract][Full Text] [Related]
34. Compliance, persistence, and switching patterns for ACE inhibitors and ARBs.
Vegter S; Nguyen NH; Visser ST; de Jong-van den Berg LT; Postma MJ; Boersma C
Am J Manag Care; 2011 Sep; 17(9):609-16. PubMed ID: 21902446
[TBL] [Abstract][Full Text] [Related]
35. Anti-hypertensive drug utilization in Continental Portugal (1999-2004).
Furtado C; Pinto M
Rev Port Cardiol; 2006 Mar; 25(3):273-92. PubMed ID: 16789402
[TBL] [Abstract][Full Text] [Related]
36. Prevalence of the prescribing of potentially inappropriate medications at ambulatory care visits by elderly patients covered by the Taiwanese National Health Insurance program.
Lai HY; Hwang SJ; Chen YC; Chen TJ; Lin MH; Chen LK
Clin Ther; 2009 Aug; 31(8):1859-70. PubMed ID: 19808145
[TBL] [Abstract][Full Text] [Related]
37. Blood pressure reduction and renin-angiotensin system inhibition for prevention of congestive heart failure: a meta-analysis.
Verdecchia P; Angeli F; Cavallini C; Gattobigio R; Gentile G; Staessen JA; Reboldi G
Eur Heart J; 2009 Mar; 30(6):679-88. PubMed ID: 19168534
[TBL] [Abstract][Full Text] [Related]
38. Economic impact of switching from valsartan to other angiotensin receptor blockers in patients with hypertension.
Signorovitch J; Zhang J; Wu EQ; Latremouille-Viau D; Yu AP; Dastani HB; Kahler KH
Curr Med Res Opin; 2010 Apr; 26(4):849-60. PubMed ID: 20141381
[TBL] [Abstract][Full Text] [Related]
39. Assessment of the use of angiotensin receptor blockers in major European markets among paediatric population for treating essential hypertension.
Balkrishnan R; Phatak H; Gleim G; Karve S
J Hum Hypertens; 2009 Jun; 23(6):420-5. PubMed ID: 19052566
[TBL] [Abstract][Full Text] [Related]
40. Dual blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in chronic kidney disease.
Song JH; Cha SH; Hong SB; Kim DH
J Hypertens Suppl; 2006 Mar; 24(1):S101-6. PubMed ID: 16601562
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
